Immunotherapy for liver tumors: present status and future prospects.
Increasing evidence suggests that immune responses are involved in the control of cancer and that the immune system can be manipulated in different ways to recognize and attack tumors. Progress in immune-based strategies has opened new therapeutic avenues using a number of techniques destined to eliminate malignant cells. In the present review, we overview current knowledge on the importance, successes and difficulties of immunotherapy in liver tumors, including preclinical data available in animal models and information from clinical trials carried out during the lasts years. This review shows that new options for the treatment of advanced liver tumors are urgently needed and that there is a ground for future advances in the field.
Matar
Pablo
P
Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Santa Fe 3100, (2000) Rosario, Argentina. matarpablo@hotmail.com
Alaniz
Laura
L
Rozados
Viviana
V
Aquino
Jorge B
JB
Malvicini
Mariana
M
Atorrasagasti
Catalina
C
Gidekel
Manuel
M
Silva
Marcelo
M
Scharovsky
O Graciela
OG
Mazzolini
Guillermo
G
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D016207:Cytokines / Q000276:immunology / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007107:Immune System / Q000502:physiology; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D008099:Liver / Q000276:immunology / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000276:immunology
D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D016207:Cytokines